# Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

> **NCT06669013** · PHASE3 · RECRUITING · sponsor: **N.N. Petrov National Medical Research Center of Oncology** · enrollment: 40 (estimated)

## Conditions studied

- Bone Sarcoma
- Embryonal Rhabdomyosarcoma
- Alveolar Rhabdomyosarcoma

## Interventions

- **DRUG:** dinutuximab beta

## Key facts

- **NCT ID:** NCT06669013
- **Lead sponsor:** N.N. Petrov National Medical Research Center of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669013, "Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06669013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*